Abstract:Objective To investigate the clinical efficacy of Enteritis No. 1 prescription in the treatment of ulcerative colitis (UC) of large intestine damp-heat type and its effects on serum levels of inflammatory factors. Methods Sixty patients with UC of large intestine damp-heat type were equally and randomly divided into control group and treatment group. The control group received 1.0 g of mesalazine suppositories, while the treatment group received Enteritis No. 1 prescription retention enema. Both groups received two courses of treatment (once every night, 1 month for a course). After two courses of treatment, serum levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were measured by enzyme-linked immunosorbent assay. The serum levels of IL-6 and TNF-α, changes in Sutherland Disease Activity Index (SDAI), and treatment outcomes were compared between the two groups. Results There was a significant difference in the distribution of treatment outcomes between the two groups (P<0.05). After treatment, both groups showed significantly reduced serum levels of IL-6 and TNF-α and SDAI (P<0.05). However, the treatment group had significantly greater reductions in the above indices than the control group (P<0.05). Conclusion Enteritis No.1 prescription retention enema can significantly reduce serum levels of IL-6 and TNF-α and has good clinical efficacy in the treatment of UC of large intestine damp-heat type.